1月23日早盘，港股通创新药板块强势反弹，高弹性港股通创新药ETF（520880）急速冲上2%！成份股 方面，云顶新耀、映恩生物-B领衔涨势，权重股康方生物涨超5%。 消息面，1月22日，商务部联合国家发展改革委、国家医保局等9部门印发《关于促进药品零售行业高质 量发展的意见》，明确提出鼓励创新药、参比制剂等进入零售药店销售渠道，并推动电子处方流转平台 建设，支持实体医疗机构与互联网医院与零售药店对接，优化购药体验。 分析人士指出，该政策旨在强化药品零售端的专业服务功能，提升创新药可及性，尤其为高值创新药 （如CAR-T）通过商保目录补充医保保障缺口提供落地路径。 二级市场资金提前埋伏，此前港股通创新药板块连阴6日，资金频频借道港股通创新药ETF（520880） 逢跌吸筹。数据显示，本周以来，520880累计获超2.3亿元资金净申购，最新份额升至45.38亿份，续创 历史新高！ 一键投资创新药，认准高弹性T+0利器——港股通创新药ETF（520880）及其场外联接基金 （025221），其跟踪的恒生港股通创新药精选指数具备三大独特优势，配置价值突出： 1、纯粹，全面。不含CXO，纯正创新药！全面覆盖创新药研发 ...

Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a strong increase, reaching a peak price of 2.88% and currently up by 2.52% [1] - Key performing stocks within the ETF include China Biologic Products, BeiGene, and Hansoh Pharmaceutical, with respective increases of 5.21%, 3.53%, and 3.14% [1] - The market anticipates more international collaboration opportunities for Chinese innovative drug companies following the JPM Healthcare Conference held from January 12 to 15, 2026 [2][3] Group 2 - West Securities predicts that the Hong Kong innovative drug sector will continue to show structural trends in 2026, with accelerated BD (business development) overseas driving the convergence of drug price differences between China and the U.S. [3] - Huafu Securities emphasizes that innovation will be a clear focus in 2026, particularly in cutting-edge technology platforms such as gene therapy and small nucleic acids [3] - The top ten weighted stocks in the Hang Seng Stock Connect Innovative Drug Select Index include Kangfang Biologics, CSPC Pharmaceutical Group, BeiGene, and China Biologic Products [3]

Core Viewpoint - The biopharmaceutical sector is currently underperforming due to multiple factors, including a lack of significant business development catalysts and external regulatory concerns, yet it remains crucial to maintain close attention to this sector as favorable macroeconomic conditions are emerging [1][2]. Group 1: Current Market Conditions - The biopharmaceutical sector is facing challenges such as the absence of major business development catalysts and the impact of potential regulatory measures from the Trump administration regarding Chinese innovative drugs [1]. - Recent volatility in stock prices, particularly in Hong Kong and A-shares, indicates a market correction that may lead to a focus on companies with genuine clinical value and performance [2]. Group 2: Investment Opportunities - The current environment presents a unique buying opportunity for high-quality innovative drug companies, as the market is expected to gradually shift towards those with proven clinical efficacy [2]. - The investment landscape for innovative drugs has entered an alpha phase, where stock selection factors are becoming more significant than market trends [2]. Group 3: Asset Rebalancing - The pharmaceutical sector may experience asset rebalancing across three dimensions: U.S.-China asset dynamics, a shift towards large-cap blue-chip companies, and internal balance within the sector, including medical devices and services [3].